S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
NASDAQ:IBRX

ImmunityBio (IBRX) Stock Price, News & Analysis

$4.91
-0.33 (-6.30%)
(As of 04/18/2024 ET)
Today's Range
$4.91
$5.28
50-Day Range
$3.50
$6.17
52-Week Range
$1.25
$6.93
Volume
3.51 million shs
Average Volume
4.02 million shs
Market Capitalization
$3.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

ImmunityBio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1.8% Upside
$5.00 Price Target
Short Interest
Bearish
41.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of ImmunityBio in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.68) to ($0.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.10 out of 5 stars

Medical Sector

909th out of 919 stocks

Biological Products, Except Diagnostic Industry

149th out of 151 stocks

IBRX stock logo

About ImmunityBio Stock (NASDAQ:IBRX)

ImmunityBio, Inc. is a clinical-stage biotechnology company that focuses on developing next-generation therapies and vaccines to enhance the immune system's ability to fight cancer and infectious diseases. Guided by its mission to improve patient outcomes, ImmunityBio harnesses cutting-edge immunotherapy and cell therapy platforms to stimulate and sustain robust immune responses. The company's dedication to innovative research and development sets it apart in biotech.

In the rapidly evolving field of biotechnology, ImmunityBio, Inc. has emerged as a prominent player dedicated to developing innovative therapies and vaccines that harness the natural power of the immune system to combat cancer and infectious diseases. With a comprehensive portfolio of immunotherapy and cell therapy platforms, the company aims to create durable and safe protection against diseases, bolstering the potential for improved patient outcomes. This article provides an in-depth analysis of ImmunityBio, Inc., encompassing its company overview, management team, financial information, valuation, market performance, industry analysis, growth opportunities, and risks and challenges.

Headquartered in California, ImmunityBio, Inc. operates with a global presence, leveraging its scientific expertise and strategic partnerships to advance its mission. ImmunityBio, Inc. offers a range of products and services centered around immunotherapy and cell therapy. These include novel cancer vaccines, targeted bi-specific fusion proteins, and personalized cell-based therapies. The company aims to provide patients with durable protection against diseases and unlock new treatment possibilities by employing a multifaceted approach.

The leadership team at ImmunityBio, Inc. plays a crucial role in driving the company's vision forward. Led by Executive Chairman and Global Chief Medical Officer Patrick Soon-Shiong, the team comprises seasoned professionals with diverse expertise in biotechnology, medicine, and business. Each member brings a wealth of experience and a strong track record of achievements, collectively contributing to the company's success.

In recent years, ImmunityBio, Inc. has demonstrated steady growth and financial resilience. The company has recorded increasing revenues, driven by the progress of its clinical programs and strategic partnerships. Moreover, ImmunityBio, Inc. has implemented efficient cost management strategies to improve profitability and optimize resources. These positive trends indicate the company's potential for long-term success.

ImmunityBio, Inc.'s valuation metrics, such as the price-to-earnings ratio and price-to-book ratio, demonstrate its strong growth prospects relative to industry peers. Investor sentiment remains favorable due to the company's robust pipeline, innovative therapies, and potential for market disruption. As a result, ImmunityBio, Inc.'s valuation continues to reflect optimism for future performance.

ImmunityBio, Inc. has exhibited a dynamic stock performance, with significant price movements and trading volume fluctuations. Recent news and events related to the company's clinical trial results, regulatory approvals, or strategic partnerships have influenced its share price. Investors closely monitor these developments to gauge the company's market position and growth potential.

Operating in the biotechnology sector, ImmunityBio, Inc. navigates a competitive landscape characterized by rapid advancements and intense research and development efforts. The company faces competition from established pharmaceutical companies and emerging biotech firms, all striving to bring innovative therapies to market. However, ImmunityBio, Inc. differentiates itself through its unique approach that focuses on leveraging the natural immune system.

The company's comprehensive portfolio of immunotherapy and cell therapy platforms provides a competitive advantage. ImmunityBio, Inc. aims to create long-lasting and durable responses against diseases by targeting the immune system, which sets it apart from traditional treatment modalities. This innovative strategy positions the company favorably in an industry increasingly recognizing immunotherapies' potential.

ImmunityBio, Inc. possesses several growth opportunities that can propel its future success. The company's robust pipeline and ongoing clinical trials offer the potential for regulatory approvals and commercialization of its therapies. The successful completion of pivotal trials and subsequent market entry can lead to revenue growth and increased market share.

Additionally, ImmunityBio, Inc. can explore expansion into new markets and indications. The company's immunotherapy and cell therapy platforms have applications beyond cancer and infectious diseases, providing avenues for diversification and broadening its target patient population. Expanding into emerging fields such as gene therapy or exploring synergistic partnerships with complementary biotech companies can further bolster its growth prospects.

While ImmunityBio, Inc.'s future outlook appears promising, it faces various risks and challenges inherent in the biotechnology industry. Regulatory hurdles, such as the stringent requirements for clinical trial approvals and market authorizations, can pose delays and uncertainties in the development and commercialization process. Adherence to rigorous safety and efficacy standards is paramount to gaining regulatory approvals and ensuring patient safety.

Market competition remains intense, with other biotech companies vying for similar target indications. The emergence of new technologies or therapies that outperform or disrupt existing treatment modalities may impact the market adoption of ImmunityBio, Inc.'s products. The company must continually innovate and stay at the forefront of scientific advancements to maintain a competitive edge.

Moreover, the biotechnology industry is subject to inherent scientific and clinical uncertainties. While ImmunityBio, Inc.'s therapies show promising results, there is always the possibility of unexpected outcomes or challenges during clinical trials. Robust risk management strategies, thorough research protocols, and continuous trial data monitoring are essential to mitigate these uncertainties.

Additionally, market dynamics, such as changes in reimbursement policies or healthcare regulations, can influence the adoption and commercial success of ImmunityBio, Inc.'s therapies. The company must adapt to evolving market conditions and navigate complex healthcare systems to ensure broad patient access to its innovative treatments.

IBRX Stock Price History

IBRX Stock News Headlines

ImmunityBio (NASDAQ:IBRX) Shares Down 8.1%
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Financial Contrast: ImmunityBio (IBRX) vs. Its Rivals
ImmunityBio (IBRX) vs. Its Rivals Critical Survey
ImmunityBio: Q4 Earnings Insights
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
IBRX Jan 2025 1.500 put
IBRX Jul 2024 1.000 put
IBRX Jan 2026 1.500 put
IBRX Oct 2024 3.500 call
IBRX Jan 2025 5.500 put
ImmunityBio, Inc. (IBRX)
IBRX May 2024 7.500 put
IBRX Mar 2024 3.500 call
IBRX Mar 2024 7.500 put
ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?
ImmunityBio: Buy Low Now Vs. Buy High Later
See More Headlines
Receive IBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/18/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IBRX
Fax
N/A
Employees
628
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-4.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-583,200,000.00
Net Margins
-93,761.41%
Pretax Margin
-93,873.32%

Debt

Sales & Book Value

Annual Sales
$620,000.00
Book Value
($0.88) per share

Miscellaneous

Free Float
112,382,000
Market Cap
$3.55 billion
Optionable
Optionable
Beta
1.23
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Patrick Soon-Shiong F.A.C.S. (Age 71)
    FRCS (C), M.Sc., Executive Chairman of the Board, Global Chief Scientific & Medical Officer
    Comp: $629.19k
  • Mr. Richard Gerald Adcock (Age 55)
    President, CEO & Director
    Comp: $849.45k
  • Mr. David C. Sachs (Age 46)
    CFO, Principal Financial Officer & Principal Accounting Officer
    Comp: $533.33k
  • Dr. Barry J. Simon M.D. (Age 59)
    Chief Corporate Affairs Officer & Director
  • Dr. Leonard S. Sender M.D.
    Chief Operating Officer
  • Dr. Enrique Diloné Ph.D. (Age 57)
    RAC, Chief Technology Officer
  • Mr. Jason R. Liljestrom (Age 41)
    General Counsel & Corporate Secretary
  • Ms. Sarah Singleton
    Chief Communications Officer & Head of Patient Advocacy
  • Dr. Sandeep K. Reddy M.D.
    Chief Medical Officer
  • Dr. Hans Georg Klingemann M.D. (Age 74)
    Ph.D., Chief Science Officer of Cellular

IBRX Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunityBio stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunityBio in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" IBRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IBRX, but not buy additional shares or sell existing shares.
View IBRX analyst ratings
or view top-rated stocks.

What is ImmunityBio's stock price target for 2024?

1 equities research analysts have issued twelve-month price targets for ImmunityBio's stock. Their IBRX share price targets range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price.
View analysts price targets for IBRX
or view top-rated stocks among Wall Street analysts.

How have IBRX shares performed in 2024?

ImmunityBio's stock was trading at $5.02 at the beginning of the year. Since then, IBRX stock has decreased by 2.2% and is now trading at $4.91.
View the best growth stocks for 2024 here
.

When is ImmunityBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IBRX earnings forecast
.

How were ImmunityBio's earnings last quarter?

ImmunityBio, Inc. (NASDAQ:IBRX) announced its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by $0.01. The business had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.03 million.

What ETFs hold ImmunityBio's stock?
Who are ImmunityBio's major shareholders?

ImmunityBio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Courier Capital LLC (0.00%) and Brookstone Capital Management (0.00%). Insiders that own company stock include Barry J Simon, Cheryl Cohen, John Owen Brennan, Michael D Blaszyk and Richard Adcock.
View institutional ownership trends
.

How do I buy shares of ImmunityBio?

Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IBRX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners